US equities
|
NVDA
$236.73
▲+1.19%
SPCX
$166.84
▲+4.96%
MU
$1,066.90
▼-0.74%
TSLA
$377.71
▲+1.92%
MSFT
$526.87
▲+1.80%
INTC
$117.26
▼-1.73%
SNDK
$1,731.20
▲+0.65%
META
$743.00
▲+2.05%
NVDA
$236.73
▲+1.19%
SPCX
$166.84
▲+4.96%
MU
$1,066.90
▼-0.74%
TSLA
$377.71
▲+1.92%
MSFT
$526.87
▲+1.80%
INTC
$117.26
▼-1.73%
SNDK
$1,731.20
▲+0.65%
META
$743.00
▲+2.05%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
57.49
+0.31 (+0.55%)
Delayed Quote
Updated: 10:21 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioMarin Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
3 Healthcare Stocks That Fall Short
September 28, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Via
StockStory
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
↗
September 18, 2026
BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth...
Via
MarketBeat
3 Mid-Cap Stocks We Keep Off Our Radar
September 15, 2026
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
Via
StockStory
BioMarin Pharmaceutical (NASDAQ:BMRN) Forms Tight Breakout Setup With Strong Technicals
↗
September 14, 2026
Via
Chartmill
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead
September 08, 2026
BioMarin Pharmaceutical trades at $66.53 and has moved in lockstep with the market. Its shares have returned 9.3% over the last six months while the S&P 500 ...
Via
StockStory
Topics
Stocks
BioMarin (NASDAQ:BMRN) Stands Out as an Undervalued Stock with Solid Fundamentals
↗
August 24, 2026
Via
Chartmill
BioMarin Pharmaceutical (NASDAQ:BMRN): A Value Stock with Strong Fundamentals
↗
July 27, 2026
Via
Chartmill
BioMarin Pharmaceutical (NASDAQ:BMRN) Presents a High-Quality Breakout Setup with Strong Technical Ratings
↗
July 25, 2026
Via
Chartmill
3 Value Stocks We Think Twice About
August 31, 2026
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via
StockStory
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
August 19, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...
Via
StockStory
Topics
Artificial Intelligence
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today
August 19, 2026
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alest...
Via
StockStory
3 Cash-Producing Stocks We Find Risky
August 13, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Via
StockStory
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating
↗
July 04, 2026
Via
Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals
↗
June 10, 2026
Via
Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Opportunity with Strong Fundamentals and Accelerating Growth
↗
May 19, 2026
Via
Chartmill
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth
↗
August 12, 2026
BioMarin Pharmaceutical (NASDAQ:BMRN) outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian...
Via
MarketBeat
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know
August 10, 2026
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raise...
Via
StockStory
BioMarin Pharmaceutical Q2 Earnings Call Highlights
↗
August 06, 2026
BioMarin Pharmaceutical (NASDAQ:BMRN) reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed...
Via
MarketBeat
Topics
Earnings
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations
August 06, 2026
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 19.9% year on year ...
Via
StockStory
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect
August 04, 2026
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Thursday after the bell. Here’s what investors should know. BioMarin Pha...
Via
StockStory
1 Profitable Stock with Impressive Fundamentals and 2 We Turn Down
August 03, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
2 Reasons to Avoid BMRN and 1 Stock to Buy Instead
July 17, 2026
BioMarin Pharmaceutical trades at $59.99 per share and has stayed right on track with the overall market, gaining 6.5% over the last six months. At the same ...
Via
StockStory
Topics
Artificial Intelligence
1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid
July 13, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via
StockStory
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore
June 29, 2026
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Via
StockStory
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off
June 26, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
Via
StockStory
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
June 24, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
2 Profitable Stocks Worth Your Attention and 1 We Find Risky
June 11, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
↗
May 30, 2026
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.
Via
The Motley Fool
Topics
Regulatory Compliance
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
May 21, 2026
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 7.3% in the afternoon session after the company announced positive resu...
Via
StockStory
1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky
May 21, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
